Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Teva denies CEO weighing an exit over board's meddling

Clearly Israel is full of chatter about Teva Pharmaceutical Industries and its latest round of cost-cutting plans. The latest, according to an Israeli television report: CEO Jeremy Levin is considering making an exit. It's not the first such suggestion; During the company's second-quarter earnings call, Goldman Sachs analyst Jami Rubin wondered aloud about the board's support--or lack thereof--for Levin.

Eli Lilly's board elects multinational financial leader

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Teva ex-chairman: Execs should share layoffs pain with 10% pay cut

That Teva workers are striking to protest job cuts isn't all that unusual in the pharma business these days. That they're protesting executive pay is somewhat more unusual. That a prominent shareholder advises an accompanying pay cut for top executives and directors? That's definitely unusual.

Former FDA commissioner joins J&J board

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Teva halts Israeli layoff plans amid pressure from labor, government

Teva Pharmaceutical Industries will back off its layoff plans in Israel--at least for now. Thanks to vociferous and colorful opposition from labor, plus worker support from politicians, Teva now pledges to negotiate with unions before cutting jobs.

Irate Teva reps vow to strike against Israeli job cuts

The job-cutting news out of Teva Pharmaceutical Industries has spawned some protest--on both sides of the issue. Israeli unions promise to strike if layoffs hit home--and, as if to pre-empt that talk, one Teva executive claims the cuts aren't nearly so bad as the media suggests.

Novartis whacks vaccine jobs as it eyes unit for disposal

The report this week that Novartis'  vaccine and diagnostic operation is one the company's  execs might want to unload  will not surprise employees at its Emeryville, CA, operation, where four dozen workers on the vaccine side have been given layoff notices.

Neuraltus names Richard Casey president, CEO

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Teva plots 5,000 more job cuts in $2B savings drive

Teva Pharmaceutical Industries is already in the middle of a big cost-cutting push. And it's about to get bigger. The Israel-based generics giant plans to lay off up to 5,000 people, or about 10% of its work force, in a bid to squeeze $2 billion out of annual costs by 2017.

PhIII antibiotic developer gets a new name, new CEO in makeover

The New Haven, CT-based biotech Rib-X is undergoing a makeover. The biotech has a new name and is now being run by a new management team drawn in by a new lead investor. But it's still focused on the same lead antibiotic: delafloxacin.